(Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Thursday recommended meningitis B vaccines for people at high risk aged 10 to 25, a population that Pfizer Inc and Novartis criticized as too narrow.
Pfizer's Trumenba, like Novartis' new vaccine Bexsero, recently won U.S. marketing approval to treat the "B" strain of the deadly bacterium in that age group.
19:22 2017 NFL Draft: Clemson, Ohio State football stars lead underclassmen going pro13
15:02 U.S housing starts surge in December; jobless claims near 43-year low13
05:09 Sterling slides to 3-month lows on 'hard Brexit' fears13
01:03 Sterling slides to three-month lows on 'hard Brexit' fears15